Viewpoint: A shot in the arm for generics producers
Domino inksThere is nowhere to hide from the Falsified Medicines Directive. It impacts generics producers in the same way as any other drug manufacturer or re-packager selling into Europe. With just under 48 months to go before the deadline, which is likely to be mid-2018, the clock is ticking for all producers to get their house in order.
The subject was hot on the agenda at the European Generics Association (EGA) meeting in Madrid earlier this month. As generics manufacturers often supply products with much lower margins than patented drug producers, their budgets are restricted when it comes to new investment – which is why many of them have been holding out until the last minute to find the ‘best-fit’ solution for their businesses.
Related Posts
60,000 Smuggled Cigarettes Seized at Jaipur Airport
Two passengers were detained by the Customs Department here after 60,000...
Foreign brands unite to fight fakes
NEW DELHI: Two weeks ago, lawyers from Tommy Hilfiger, Lacoste, Calvin Klein,...
IGI airport sees rise in gold seizures from foreign countries
The Indira Gandhi International Airport (IGI) witnessed a significant surge in...
How mobile shopping is giving the cycle trade counterfeiting headaches
With retail spend via mobiles and tablets forecast set to hurtle toward £53.6bn a...